Research programme: immunological disorder therapeutics - Jeffrey Modell Foundation/Pfizer Centers for Therapeutic Innovation

Drug Profile

Research programme: immunological disorder therapeutics - Jeffrey Modell Foundation/Pfizer Centers for Therapeutic Innovation

Latest Information Update: 21 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jeffrey Modell Foundation; Pfizer Centers for Therapeutic Innovation
  • Developer Pfizer Centers for Therapeutic Innovation
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Immunological disorders

Most Recent Events

  • 08 Jul 2015 Pfizer’s Centers for Therapeutic Innovation and the Jeffrey Modell Foundation agree to co-develop therapeutics for immunological disorders
  • 08 Jul 2015 Early research in Immunological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top